DexmedetOmidine Complement Treats Chronic insOmnia and Improves Circadian Rhythm (DOCTOR)
Status:
Recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
It has been reported that dexmedetomidine, alpha-2 adrenoceptor agonist, can activate
endogenous neural sleep pathways in the central nervous system. This randomised,
double-blinded and controlled trial was designed to investigate whether dexmedetomidine can
improve/treat chronic insomnia patients. Its effects on sleep quality and improvement, EEG
and circadian rhythm, brain connectivity, cognition and biomarker changes are determined.